Drug repurposing of glycerol phenylbutyrate for children with SLC6A1-related neurodevelopmental disorder: A prospective open-label case series.
Glycerol phenylbutyrate was associated with improvements in individualized outcomes in children with SLC6A1-NDD, however, personalized goal attainment measures are susceptible to expectation and observer bias in open-label study designs.